For the Inventor, By the Inventor

Enter assignee name

Emeryville, CA, United States of America

Eureka Therapeutics, Inc.

USPTO Granted Patents = 52

% Expired Patents = 11.5

EPO Patents = 12

Trademarks = 2

Forward Citations = 177

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Cheng Liu (41 out of 49 patents)

Hong Liu (21 out of 22 patents)

Su Yan (20 out of 20 patents)

4. Renier J Brentjens (18 out of 22 patents)

5. Eric L Smith (17 out of 88 patents)

6. Yiyang Xu (16 out of 16 patents)

7. Jingyi Xiang (11 out of 12 patents)

8. Zhiyuan Yang (9 out of 12 patents)

9. Lucas Horan (9 out of 9 patents)

10. Tao Dao (8 out of 11 patents)

11. David A Scheinberg (8 out of 51 patents)

12. Jingwei Lu (7 out of 7 patents)

13. Vivien Wai-Fan Chan (6 out of 6 patents)

14. Pengbo Zhang (6 out of 6 patents)

15. Lianxing Liu (5 out of 5 patents)

Core Competencies:

Chimeric Antigen Receptors

G-Protein Coupled Receptor

Antibodies

B-Cell Maturation Antigen

Fc Receptor-Like 5

Mucin-16

Prostate-Specific Membrane Antigen

T Cell Receptor-Like Antibodies

Nucleic Acid Molecules

Oncogene Products

PD-1 Immune Modulating Agents

Modified Glycoproteins

52 patents: Sort by Forward Citations

1. 12655211 - ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USE (2026-06-16),

2. 12636375 - Antibodies targeting Fc receptor-like 5 and methods of use (2026-05-26),

3. 12617866 - HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF (2026-05-05),

4. 12479924 - CONSTRUCTS SPECIFICALLY RECOGNIZING GLYPICAN 3 AND USES THEREOF (2025-11-25),

5. 12168696 - Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer (2024-12-17),

6. 12139538 - Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof (2024-11-12),

7. 11993661 - Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof (2024-05-28),

8. 11981742 - Antibody agents specific for human CD19 and uses thereof (2024-05-14),

9. 11976105 - Antibody/T-cell receptor chimeric constructs and uses thereof (2024-05-07),

10. 11965021 - Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof (2024-04-23),

11. 11866478 - Nucleic acid molecules encoding chimeric antigen receptors targeting G-protein coupled receptor (2024-01-09),

12. 11827672 - Constructs trageting CD22 and uses thereof (2023-11-28),

13. 11820806 - Chimeric antigen receptors targeting G-protein coupled receptor and uses thereof (2023-11-21),

14. 11725059 - Antibodies targeting B-cell maturation antigen and methods of use (2023-08-15),

15. 11673957 - Anti-ROR2 antibodies (2023-06-13),

Company Overview

Eureka Therapeutics, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of innovative therapies utilizing Chimeric Antigen Receptors (CARs). The company focuses on harnessing the power of the immune system to target and eliminate cancer cells, employing advanced technologies such as G-Protein Coupled Receptors and T Cell Receptor-Like Antibodies. Eureka is dedicated to addressing unmet medical needs in oncology through its cutting-edge research and development efforts.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

52 Patents

#13 in Emeryville, CA

#1,588 in California

#6,760 in US

#13,545 in the World

Emeryville, CA, United States of America

Eureka Therapeutics, Inc.

Forward Citations = 177

45 inventors:

Cheng Liu (41 out of 49 patents)

Hong Liu (21 out of 22 patents)

Su Yan (20 out of 20 patents)

4. Renier J Brentjens (18 out of 22 patents)

5. Eric L Smith (17 out of 88 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Eureka Therapeutics, Inc.. Retrieved from https://idiyas.com/company/eureka-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…